Results 71 to 80 of about 148,906 (304)

Consumed by Abdominal Distention

Arthritis Care &Research, EarlyView.
Abimbola Fadairo‐Azinge, James Grenert, Brian Haas, Mary Margaretten   +3 more
wiley   +1 more source

Single Cell RNA Transcriptomics of Mantle Cell Lymphoma Reveals the Presence of Treatment‐Resistant Subclones at the Time of Diagnosis

American Journal of Hematology, EarlyView.
ABSTRACT Mantle cell lymphoma (MCL) is a B‐cell malignancy with a chronically relapsing clinical course and pronounced genetic heterogeneity. To investigate the clonal dynamics underlying early disease relapse, we performed single‐cell RNA sequencing of paired tumor samples collected at diagnosis and at first relapse. Inference of copy number variants (
Dmitry Manakov, Magdalena Klanova, Michal Kolar, Robert Ivanek, Florian Geier, Julien Roux, Tomas Zikmund, Lucie Winkowska, Eva Kriegova, Jirina Manakova, Liliana Tuskova, Silvia Spanikova, Alexandra Scasna, Marek Trneny, Pavel Klener   +14 more
wiley   +1 more source

Hodgkin Lymphoma and Castleman Disease: When One Blood Disease Can Hide Another

Case Reports in Hematology, 2017
We describe a rare case of Castleman disease associated de novo with Hodgkin lymphoma. The incidence of Castleman disease is rare; only a few studies have described it in de novo association with Hodgkin lymphoma. The patient described here complained of
L. Filliatre-Clement, H. Busby-Venner, C. Moulin, G. Roth-Guepin, A. Perrot   +4 more
doaj   +1 more source

Sjögren Disease—B Cells at the Brink: From Autoimmunity to Lymphomagenesis and the Rise of Novel B Cell–Targeted Therapies

Arthritis &Rheumatology, EarlyView.
Sjögren disease (SjD) is a common systemic autoimmune disorder characterized by inflammation of the exocrine glands, resulting in dryness. Patients frequently exhibit extraglandular manifestations affecting various organ systems. To date, there are no US Food and Drug Administration (FDA)‐approved disease‐modifying therapies for SjD. In this review, we
Rachael A. Gordon, Sara S. McCoy
wiley   +1 more source

Expression of Cyclooxygenase 2 and p-53 and their Relation with 5 Years Survival in Hodgkin\'s Lymphoma

پزشکی بالینی ابن سینا, 2012
Introduction & Objective: Hodgkin lymphoma accounts for about 1% of all cancers. Cyclooxygenase 2 (COX2) is a cytoplasmic enzyme. Oncogene, and growth factor induce over expression of COX2. COX2 is apoptotic inhibitor.
Effat Abdoli, Alireza Rastgoo Haghi, Saadat Torabian   +2 more
doaj  

One-Year Follow-Up of Non-Healing Socket in Hodgkin’s Lymphoma Patient: Case Report and Literature Review on Management Strategies

Diagnostics
Background and Clinical Significance: Sodium hypochlorite (NaOCl) is widely used in root canal treatment for its potent antiseptic and antibacterial effects.
Ahmed Ata Alfurhud
doaj   +1 more source

Hodgkin Disease (Lymphogranulomatosis) in Children

Zdorovʹe Rebenka, 2013
-
N.V. Nagornaya, E.V. Vilchevskaya, A.P. Dudchak, E.N. Marchenko, E.V. Bordyugova, A.P. Koval   +5 more
doaj   +1 more source

Rapid onset of hypercalcemia from high-grade lymphoma in the setting of HIV-related immune reconstitution inflammatory syndrome. [PDF]

, 2019
Hypercalcemia in HIV patients has been previously reported, but 1,25-(OH)2 vitamin D-mediated hypercalcemia, due to increased activity of extrarenal 1-alpha hydroxylase, is rarely described with HIV-related infections or malignancies.
Bikle, Daniel, Kim, Sarah, Kim, Stephanie J, Peluso, Michael J, Shoback, Dolores, Wang, Yongmei   +5 more
core  

Risk of Cancer among Commercially Insured HIV-Infected Adults on Antiretroviral Therapy. [PDF]

, 2016
The objective of this study was to explore the cancer incidence rates among HIV-infected persons with commercial insurance who were on antiretroviral therapy and compare them with those rates in the general population. Paid health insurance claims for 63,
Ambinder, Richard F, Casper, Corey, Dhakal, Ishwori, Haigentz, Missak, Krown, Susan E, Lee, Jeannette Y, Mitsuyasu, Ronald T, Noy, Ariela, Palefsky, Joel M   +8 more
core   +3 more sources

Single‐cell level characterization of B cell depletion and repopulation following rituximab in systemic lupus erythematosus

Arthritis &Rheumatology, Accepted Article.
Objective Rituximab, a CD20+ B cell depletion therapy, is frequently used to treat systemic lupus erythematosus (SLE). However, variability in patient response highlights the need for a deeper understanding of the underlying immune cell dynamics of B cell depletion and repopulation.
Haerin Jang, Norzawani Buang, Catherine Sutherland, Wanseon Lee, Lauren Overend, Tarran S. Rupall, Katie L. Burnham, Matthew C. Pickering, Marina Botto, Emma E. Davenport   +9 more
wiley   +1 more source